Overview
Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects
Status:
Completed
Completed
Trial end date:
2010-01-01
2010-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to investigate the pharmacokinetics, safety, and tolerability of the co-administration of VCH-222 and telaprevir in healthy subjects.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Criteria
Inclusion Criteria:- Healthy males, and/or healthy females of non-childbearing potential, aged 18 to 55
years (inclusive)
- Body mass index (BMI) between 18 and 31 kg/m2 (inclusive) and weight > 50 kg
Exclusion Criteria:
- Women of child bearing potential
- Subjects positive for Hepatitis B, Hepatitis C, or HIV
- Subjects who have participated in a clinical study involving administration of an
investigational drug within 2 months